BofA raised the firm’s price target on Alkermes (ALKS) to $31 from $28 and keeps a Neutral rating on the shares, citing a higher multiple given the recent move in biotech peer comps for the increased ...

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed ...

Fintel reports that on November 5, 2024, Stifel upgraded their outlook for Alkermes (NasdaqGS:ALKS) from Hold to Buy. Analyst ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 4.9% of Alkermes shares are owned by ...

Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

During the last three months, 9 analysts shared their evaluations of Alkermes ALKS, revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ...

Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. The investment bank said it is now “very confident ...

Among the posters, Alkermes presented results from a real-world, retrospective study of healthcare resource utilization (HCRU) and treatment patterns in patients with schizophrenia and patients with ...

Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. These figures ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Alkermes is a biopharmaceutical company primarily involved in developing treatments for central nervous system disorders. Its current lineup includes schizophrenia treatment Aristada ...